Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study

被引:21
|
作者
Barrera-Vargas, Ana [1 ]
Rosado-Canto, Rodrigo [2 ]
Merayo-Chalico, Javier [1 ]
Arreola-Guerra, Jose M. [3 ]
Mejia-Vilet, Juan M. [2 ]
Correa-Rotter, Ricardo [2 ]
Gomez-Martin, Diana [1 ]
Alcocer-Varela, Jorge [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico
[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Nephrol & Mineral Metab, Mexico City, DF, Mexico
[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Internal Med, Mexico City, DF, Mexico
关键词
lymphopenia; lupus nephritis; systemic lupus erythematosus; thrombotic microangiopathies; ENDOTHELIAL PROGENITOR CELLS; DISEASE-ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; THROMBOCYTOPENIC PURPURA; VASCULAR-LESIONS; ERYTHEMATOSUS PATIENTS; LYMPHOPENIA; CLASSIFICATION; PROGNOSIS; MANIFESTATIONS;
D O I
10.1097/RHU.0000000000000425
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Renal thrombotic microangiopathy (TMA) may be associated with lupus nephritis. Its relationship to other disease factors and its specific effect on prognosis are not precisely known. Evidence regarding these aspects is controversial, and information focusing on kidney-limited TMA in systemic lupus erythematosus (SLE) patients is scarce. Objectives The aims of this study were to identify risk factors for renal TMA in patients with lupus nephritis and to determine its impact on clinical outcomes. Methods A case-control study was performed. We studied 245 renal biopsies from SLE patients. We included patients with renal TMA, as well as control subjects adjusted for glomerulonephritis class, estimated glomerular filtration rate, activity and chronicity indices, and follow-up time. Serological and clinical features were measured at the time of the biopsy and during follow-up. Results Twenty-three patients with renal TMA and 21 control subjects were included. There were no differences in Systemic Lupus Erythematosus Disease Activity Index score, end-stage renal disease, or mortality between groups during follow-up. After multivariate analysis, lymphopenia (odds ratio, 10.69; 95% CI, 1.35-84.74) and anti-Ro antibody positivity (odds ratio, 8.96; 95% CI, 1.49-53.57) remained significantly associated with renal TMA. Conclusions Lymphopenia and anti-Ro positivity are independent risk factors for renal TMA in SLE patients. This increased risk could be a consequence of the potential role of these factors in endothelial dysfunction and damage. Outcomes were similar for patients with the same estimated glomerular filtration rate and biopsy characteristics, regardless of the presence of TMA.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 50 条
  • [21] Long-term renal outcomes of patients with non-proliferative lupus nephritis
    Kang, Eun-Song
    Ahn, Soo Min
    Oh, Ji Seon
    Kim, Yong-Gil
    Lee, Chang-Keun
    Bin Yoo
    Hong, Seokchan
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (05) : 769 - +
  • [22] Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis—a case-control study
    Yuqi Zhang
    Wei Li
    Panpan Zhang
    Jinyan Guo
    Jinlei Sun
    Jiameng Lu
    Shengyun Liu
    Arthritis Research & Therapy, 24
  • [23] Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV plus V): A long-term observational study
    Ikeuchi, Hidekazu
    Hiromura, Keiju
    Kayakabe, Ken
    Tshilela, Kadiombo Anastasie
    Uchiyama, Kazuhiko
    Hamatani, Hiroko
    Sakairi, Toru
    Kaneko, Yoriaki
    Maeshima, Akito
    Nojima, Yoshihisa
    MODERN RHEUMATOLOGY, 2016, 26 (06) : 908 - 913
  • [24] Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study
    Erre, Gian Luca
    Bosincu, Luisanna
    Faedda, Rossana
    Fenu, Patrizia
    Masala, Antonio
    Sanna, Marcella
    Taras, Loredana
    Longu, Maria Giovanna
    Piras, Marco
    Soro, Giovanni
    Satta, Andrea Ercole
    Passiu, Giuseppe
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (04) : 535 - 541
  • [25] LUPUS NEPHRITIS : CLINICAL MANIFESTATIONS AND RISK FACTORS
    Kechida, M.
    Vilalba, N. Lorenzo
    Mesfar, R.
    Funes, Y. Alvarado
    Klii, R.
    Hammami, S.
    Khochtali, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : S94 - S94
  • [26] Long noncoding RNAs (CTC-471J1.2, NeST) as epigenetic risk factors of active juvenile lupus nephritis: a case-control study
    Zedan, Mohamed M.
    Sobh, Ali
    Magdy, Alshimaa
    Korkor, Mai S.
    Attia, Zeinab R.
    Khaled, Nada
    Sadeq, Yousra
    El-Nagdy, Ahmed Hazem
    Taha, Ahmed E.
    Noureldin, Mohamed Ahmed
    Taman, Mohamed
    Mosa, Doaa Mosad
    Elnagdy, Marwa H.
    PEDIATRIC RHEUMATOLOGY, 2024, 22 (01)
  • [27] Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis
    Shin, Jung-Min
    Kim, Dam
    Kwon, Young-Chang
    Ahn, Ga-Young
    Lee, Jiyoung
    Park, Youngho
    Lee, Yeon-Kyung
    Lee, Tae-Han
    Park, Dae Jin
    Song, Yeo-Jin
    Ha, Eunji
    Kim, Kwangwoo
    Bang, So-Young
    Choi, Chan-Bum
    Lee, Hye-Soon
    Bae, Sang-Cheol
    JOURNAL OF RHEUMATIC DISEASES, 2021, 28 (03): : 150 - 158
  • [28] Differing environmental risk factors for membranous versus proliferative lupus nephritis
    MA Dooley
    CG Parks
    GS Cooper
    Arthritis Research & Therapy, 14 (Suppl 3):
  • [29] Clinical features, outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study
    Cui, H-W
    Lei, R-Y
    Zhang, S-G
    Han, L-S
    Zhang, B-A
    LUPUS, 2019, 28 (08) : 961 - 969
  • [30] Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study
    Luis, Mariana S. F.
    Bultink, Irene E. M.
    da Silva, Jose A. P.
    Voskuyl, Alexandre E.
    Ines, Luis S.
    RHEUMATOLOGY, 2021, 60 (11) : 5134 - 5141